<DOC>
	<DOCNO>NCT00243750</DOCNO>
	<brief_summary>Assessing efficacy tolerability methotrexate 15mg sc first month treatment- well tolerated methotrexate 20mg sc follow 3 month patient active anklyosing spondylitis</brief_summary>
	<brief_title>Methotrexate Ankylosing Spondylitis ( MTX AS )</brief_title>
	<detailed_description>Ankylosing spondylitis inflammatory rheumatic disease mit main affection spine . However peripheral joint , entheses eye also affect . The rheumatic symptom patient typically show good response nonsteroidal antirheumatic drug . In contrast rheumatoid arthritis ankylose spondylitis evidence therapy disease modify antirheumatic drug effective ( DMARD ) . Next study DMARD sulfasalazine , seem effective mainly peripheral joint involvement possible effect short disease duration also seem exist axial involvement , regard DMARDs small study case report . In term methotrexate small study dosage 7,5mg – 10 mg – maximally 15mg ( perorally single patient ) publish . In three open study 11- 34 patient treated methotrexate 7,5mg – maximally 15mg perorally time duration 24 week maximally 3 year certain effectiveness partly spinal symptom , partly peripheral joint involvement ( 1 , 2 , 3 ) . In double blind control study 30 50 patient respectively dosage 7,5 10mg methotrexate respectively significant effectiveness show ( 4,5 ) . To summarize , different study effectiveness could show clearly . Therapy methotrexate patient inflammatory rheumatic disease – especially rheumatoid arthritis- belongs standard therapy . In Germany methotrexate give 70 % case good effectiveness therapy first choice . In treatment psoriatic arthritis represent disease similar ankylose spondylitis regard pathogenesis , methotrexate therapy could establish dosage 20mg parenterally 25mg perorally respectively successfully . Bearing mind even surprising data methotrexate dosage treatment ankylose spondylitis . According German rheumatic register ( so-called “ rheumatologische Kerndokumentation “ , PD . Dr. A. Zink , DRFZ , Berlin ) already 20 % patient ankylose spondylitis treat methotrexate German rheumatologist . For reason make sense perform study treatment patient active ankylose spondylitis methotrexate dosage 20mg . In therapy rheumatoid arthritis combination methotrexate TNFalpha block agent lead enhancement effectiveness reduction side effect . For reason effectivenss methotrexate ankylose spondylitis also interesting regard possible combination TNFalpha block agent show successful treatment ankylose spondyltitis .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : Definite ankylose spondylitis accord New York criterion 1984 . Known ankylose spondylitis accord modify New York criterion 1984 age 18 70 year insufficient therapy nonsteroidal antirheumatic drug BASDAI &gt; 4 therapy DMARD ( sulfasalazine , hydroxychloroquine , leflunomide , methotrexate ≤ 10 mg etc . ) allow study start discontinue least 1 month study start ; elimination leflunomide colestyramin coal necessary . · therapy biologics ( TNFalpha block agent , IL1blocking agent etc . ) discontinue least 3 month study start therapy steroid ≤ 10 mg least 4 week stable study start patient willing prevent pregnancy use accepted contraceptive method end study sign informed consent patient able administer study drug exclusion pregnancy female patient childbearing potential Exclusion criterion : intake glucocorticosteroids &gt; 10 mg , therapy intraarticular steroid within last 4 week study start previous therapy methotrexate &gt; 10 mg allergy methotrexate part medication pregnancy/ lactation current severe infection , suspicion opportunistic infection ( Herpes zoster , cytomegaly , pneumocystis cariniiinfection ) within last 4 month , HIV infection malignant disease within last 5 year severe cardiac , renal , hematologic , endocrine , pulmonary , neurological , gastrointestinal ( e.g . gastroesophageal ulcer ) hepatic ( viral hepatitis , toxic liver disease etc . ) disease , uncontrolled high blood pressure , recurrent thrombosis/ emboly , significant disease hematopoesis . active immunization within last 4 week immunization plan study time significant finding laboratory : hemoglobin &lt; 8,5 mg/dl , leukopenia &lt; 3,5 /nl , thrombopenia &lt; 100 /nl , creatinine &gt; 200 µmol/l , liver enzymes alkaline phosphate &gt; 1,5fold upper limit normal significant pathologic finding physical examination particpation another clinical trial last 30 day substance abuse , e.g . cocaine , heroine , alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2003</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>trial</keyword>
	<keyword>methotrexate</keyword>
</DOC>